These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Perl AE; Kasner MT; Tsai DE; Vogl DT; Loren AW; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Frey NV; Nasta SD; Hexner EO; Dierov JK; Swider CR; Bagg A; Gewirtz AM; Carroll M; Luger SM Clin Cancer Res; 2009 Nov; 15(21):6732-9. PubMed ID: 19843663 [TBL] [Abstract][Full Text] [Related]
4. [Germ cell testicular tumors: understanding the kinetics of serum human chorionic gonadotropin during chemotherapy]. Riedinger JM; Eche N; Fargeot P Ann Biol Clin (Paris); 2008; 66(5):515-21. PubMed ID: 18957340 [TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy of carboplatin and paclitaxel for metastatic melanoma. Sato Y; Uhara H; Ashida A; Okuyama R J Dermatol; 2013 Dec; 40(12):1050-1. PubMed ID: 24330169 [No Abstract] [Full Text] [Related]
6. Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1. Niessner H; Kosnopfel C; Sinnberg T; Beck D; Krieg K; Wanke I; Lasithiotakis K; Bonin M; Garbe C; Meier F Exp Dermatol; 2017 Jul; 26(7):598-606. PubMed ID: 28423208 [TBL] [Abstract][Full Text] [Related]
7. [A case of malignant melanoma from the esophagus responding to weekly paclitaxel therapy]. Kakudo Y; Yoshioka T; Noguchi S; Hanada M; Otsuka K; Sakayori M; Chiba N; Shibata H; Kato S; Shimodaira H; Ohori H; Takahashi S; Takahashi M; Yamaura G; Yasuda K; Ishioka C Gan To Kagaku Ryoho; 2006 Jul; 33(7):969-72. PubMed ID: 16835489 [TBL] [Abstract][Full Text] [Related]
8. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer]. Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022 [TBL] [Abstract][Full Text] [Related]
9. [Germ cell testicular tumors: understanding the kinetics of serum alpha-fetoprotein (AFP) during chemotherapy]. Riedinger JM; Eche N; Chevreau C; Fargeot P Ann Biol Clin (Paris); 2008; 66(5):523-30. PubMed ID: 18957341 [TBL] [Abstract][Full Text] [Related]
10. [A case of metastatic rectal cancer from serous adenocarcinoma of the ovary]. Miyake Y; Kato T; Oshima S; Iijima S; Kurokawa E; Okamoto Y; Kumazawa K; Chin R; Amemiya K; Adachi K; Kikkawa N Gan To Kagaku Ryoho; 2007 Dec; 34(13):2317-9. PubMed ID: 18079639 [TBL] [Abstract][Full Text] [Related]
11. A phase II study of REOLYSIN Mahalingam D; Fountzilas C; Moseley J; Noronha N; Tran H; Chakrabarty R; Selvaggi G; Coffey M; Thompson B; Sarantopoulos J Cancer Chemother Pharmacol; 2017 Apr; 79(4):697-703. PubMed ID: 28289863 [TBL] [Abstract][Full Text] [Related]
12. Carboplatin and vinorelbine combined with subcutaneous interleukin-2 in metastatic melanoma with poor prognosis. Vuoristo MS; Vihinen P; Skyttä T; Tyynelä K; Kellokumpu-Lehtinen P Anticancer Res; 2009 May; 29(5):1755-9. PubMed ID: 19443399 [TBL] [Abstract][Full Text] [Related]
13. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. Ronellenfitsch MW; Brucker DP; Burger MC; Wolking S; Tritschler F; Rieger J; Wick W; Weller M; Steinbach JP Brain; 2009 Jun; 132(Pt 6):1509-22. PubMed ID: 19416948 [TBL] [Abstract][Full Text] [Related]
14. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents. Ozols RF J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Rebecca VW; Massaro RR; Fedorenko IV; Sondak VK; Anderson AR; Kim E; Amaravadi RK; Maria-Engler SS; Messina JL; Gibney GT; Kudchadkar RR; Smalley KS Pigment Cell Melanoma Res; 2014 May; 27(3):465-78. PubMed ID: 24490764 [TBL] [Abstract][Full Text] [Related]
16. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus. Jahnel J; Lackner H; Reiterer F; Urlesberger B; Urban C Klin Padiatr; 2012 Oct; 224(6):395-7. PubMed ID: 23070861 [No Abstract] [Full Text] [Related]
17. A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer. Ferrari D; Fiore J; Codecà C; Di Maria G; Bozzoni S; Bordin V; Caldiera S; Luciani A; Zonato S; Floriani I; Foa P Anticancer Drugs; 2009 Mar; 20(3):185-90. PubMed ID: 19396017 [TBL] [Abstract][Full Text] [Related]
19. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107 [TBL] [Abstract][Full Text] [Related]
20. Nab-paclitaxel in patients with metastatic melanoma. Leon-Ferre RA; Markovic SN Expert Rev Anticancer Ther; 2015; 15(12):1371-7. PubMed ID: 26536477 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]